- Issue price
- ₹344per share
- Issue size
- 1,38,22,116 sharesAmount set with price
- Face value
- ₹1per equity share
- Lot size
- 43 sharesMin. ₹14,792 at the upper price
- Anchor biddingWed, 2026
- OpensThu, 2026
- ClosesMon, 2026
- AllotmentWed, 2026
- ListingFri, 2026
Dates marked in the offer document as tentative. Times in IST.
Information only, not investment advice. This page provides information compiled from official offer documents for information purposes only. It is not investment advice or a recommendation to apply for, buy or sell any security. We are not a SEBI-registered investment adviser or research analyst. Investments in IPOs are subject to market risks; read the offer document carefully before investing.
Issue details
- Issue type
- Book built, fresh issue and offer for sale
- Fresh issue
- 0 shares
- Offer for sale
- 1,38,22,116 shares
- Total issue
- 1,38,22,116 shares
- Face value
- ₹1
- Listing at
- NSE, BSE
- RHP date
- 9 Oct 2026
Source: Red Herring Prospectus dated 9 Oct 2026Updated
Reservation
Share of the total issue- Employees100.0%
| Category | Shares | Of net offer | Stated in RHP |
|---|---|---|---|
| Retail individual investors | — | — | 35% |
| Non-institutional investors (NII) | — | — | 15% |
| Qualified institutional buyers (QIB) | — | — | 50% |
| Anchor investors | — | — | — |
| Employees | 2,50,000 | 100.00% | — |
Source: Red Herring Prospectus dated 9 Oct 2026Updated
Subscription
Category-wise subscription is published by the exchanges while the issue is open. It appears here once the figures are added.
Valuation
FY 2025-26, pre-issue- EPS (basic)
- ₹6.67
- EPS (diluted)
- ₹6.48
- RoNW
- 10.60%
- NAV per share (As on June 30, 2026)
- ₹64.35
Source: Red Herring Prospectus dated 9 Oct 2026Updated
Financials
Consolidated, restated · ₹ crore| Period ended | 30 Jun 20263 months | 31 Mar 2026FY 2025-26 | 31 Mar 2025FY 2024-25 | 31 Mar 2024FY 2023-24 |
|---|---|---|---|---|
| Revenue from operations | 351.67 | 1,210.50 | 1,024.88 | 901.60 |
| Total income | 354.33 | 1,218.73 | 1,035.96 | 908.59 |
| EBITDA | 48.58 | 170.66 | 128.02 | 110.05 |
| Profit after tax | 15.09 | 69.08 | 25.15 | -7.35 |
| Net worth | 709.37 | 695.46 | 565.73 | 540.09 |
| Reserves and surplus | 699.56 | 685.65 | 555.97 | 530.34 |
| Total assets | 1,309.00 | 1,276.43 | 1,094.90 | 970.58 |
| Total borrowing | 320.63 | 269.48 | 224.96 | 175.27 |
FY 2025-26 vs FY 2024-25: revenue +18.1%, profit after tax +174.7%. Periods shorter than 12 months are shown as reported and are not annualised.
Source: Red Herring Prospectus dated 9 Oct 2026Updated
About the company
The company designs and manufactures Class III and Class C/D medical devices, mainly vascular intervention products such as coronary stents and balloons, and structural heart products such as TAVI systems and occluders. It sells across India, Europe and other regions through direct, hybrid and distributor models, and runs manufacturing sites in India and Thailand.
- Incorporated
- 2001
- Industry
- Medical Devices
- CIN
- U33119GJ2001PLC040121
- Website
- smtpl.com
Source: Red Herring Prospectus dated 9 Oct 2026Updated
Promoters and shareholders
| Name | Type | Before issue | After issue | Shares offered |
|---|---|---|---|---|
| Shree Hari Trust | Promoter | — | — | 27,00,000 |
| Dhirajkumar Savjibhai Vasoya | Promoter group | — | — | 20,00,000 |
| Samara Capital Markets Holding Limited | Selling shareholder | — | — | 64,79,063 |
| Kotak Pre-IPO Opportunities Fund | Selling shareholder | — | — | 13,07,875 |
| NHPEA Sparkle Holding B.V. | Selling shareholder | — | — | 13,35,178 |
Source: Red Herring Prospectus dated 9 Oct 2026Updated
Objects of the issue
| Purpose | Amount |
|---|---|
| Offer for Sale by selling shareholders; company receives no proceeds | Set with price |
| Benefits of listing, visibility and liquidity for existing shareholders | Set with price |
Source: Red Herring Prospectus dated 9 Oct 2026Updated
Peer comparison
As listed in the offer document| Company | EPS | P/E | RoNW | NAV per share |
|---|---|---|---|---|
| Poly Medicure Limited | ₹31.79 | 51.40× | 10.37% | ₹306.4 |
| Laxmi Dental Limited | ₹5.27 | 36.35× | 11.91% | ₹44.27 |
Source: Red Herring Prospectus dated 9 Oct 2026Updated
Strengths and risks
Our summary of what the offer document statesStrengths
- Holds a leading share of India's drug-eluting stent market by volume, per the industry report commissioned by the company.
- Has a broad portfolio of Class III and Class C/D devices across vascular and structural heart segments.
- Sells products in about 65 to 77 countries through direct, hybrid and distributor models.
- Owns three manufacturing sites in India and Thailand with in-house balloon catheter production.
- Holds 119 granted patents and runs R&D centres in India and Thailand.
Risks
- Operations depend on continued regulatory approvals and certifications in India, the EU and other markets, and some CE certificates expire or are under transition.
- A product registration in Brazil was cancelled and some foreign approvals were rejected or discontinued.
- Manufacturing is concentrated in three facilities, so disruptions could affect output and sales.
- Net debt to EBITDA rose to 4.89 times for the three months ended June 30, 2026 against 1.12 times for FY 2025-26.
- Contingent liabilities of ₹107.61 million are pending tax, GST and customs matters as at June 30, 2026.
Source: Red Herring Prospectus dated 9 Oct 2026Updated
Contacts
Source: Red Herring Prospectus dated 9 Oct 2026Updated
Allotment status
Check whether shares were allotted on the official pages below, using your PAN, application number or DP/client ID. Results appear once the basis of allotment is finalised.
- Allotment
- Refunds
- Demat credit
- Listing
Source: Red Herring Prospectus dated 9 Oct 2026Updated
After listing
| Listing day | Open | High | Low | Close | Close vs issue price |
|---|---|---|---|---|---|
| 23 Oct 2026 | ₹371.15 | — | — | — | — |
Work out the gain or loss on allotted shares after charges and tax →
Source: Red Herring Prospectus dated 9 Oct 2026Updated
Frequently asked questions
When does the Sahajanand Medical Technologies IPO open and close?
According to the Red Herring Prospectus, the issue opens on Thursday, 15 October 2026 and closes on Monday, 19 October 2026. These dates are tentative.
What is the Sahajanand Medical Technologies IPO price band?
The final issue price is ₹344 per share.
What is the lot size of the Sahajanand Medical Technologies IPO?
One lot is 43 shares, which is ₹14,792 at ₹344 per share.
Where will Sahajanand Medical Technologies shares list?
On NSE and BSE. The tentative listing date is Friday, 23 October 2026.
Who is the registrar of the issue?
MUFG Intime India Private Limited (SEBI registration INR000004058). Allotment status is checked on the registrar's website.
How do I check the Sahajanand Medical Technologies IPO allotment status?
The basis of allotment is expected to be finalised on Wednesday, 21 October 2026. After that, search by PAN, application number or DP/client ID on the registrar's website (MUFG Intime India Private Limited), the NSE website or the BSE website. Shares that are allotted are credited to your demat account; for an application that is not allotted, the blocked amount is released.
Related IPOs
Also managed by Motilal Oswal Investment Advisors
- B.S. SpongeTBAFiled · 1 Oct 2026
- National Stock Exchange of India₹1,785Listed · 17 Sept – 21 Sept 2026
- LCC Projects₹146Listed · 9 Sept – 11 Sept 2026
- Manipal Payment and Identity Solutions₹339Listed · 9 Sept – 11 Sept 2026
Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.